195 related articles for article (PubMed ID: 37142882)
21. mTORC1 is essential for leukemia propagation but not stem cell self-renewal.
Hoshii T; Tadokoro Y; Naka K; Ooshio T; Muraguchi T; Sugiyama N; Soga T; Araki K; Yamamura K; Hirao A
J Clin Invest; 2012 Jun; 122(6):2114-29. PubMed ID: 22622041
[TBL] [Abstract][Full Text] [Related]
22. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
Sandhöfer N; Metzeler KH; Rothenberg M; Herold T; Tiedt S; Groiß V; Carlet M; Walter G; Hinrichsen T; Wachter O; Grunert M; Schneider S; Subklewe M; Dufour A; Fröhling S; Klein HG; Hiddemann W; Jeremias I; Spiekermann K
Leukemia; 2015 Apr; 29(4):828-38. PubMed ID: 25322685
[TBL] [Abstract][Full Text] [Related]
23. mTOR regulates cell survival after etoposide treatment in primary AML cells.
Xu Q; Thompson JE; Carroll M
Blood; 2005 Dec; 106(13):4261-8. PubMed ID: 16150937
[TBL] [Abstract][Full Text] [Related]
24. A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase.
Zhou J; Toh SH; Chan ZL; Quah JY; Chooi JY; Tan TZ; Chong PSY; Zeng Q; Chng WJ
J Hematol Oncol; 2018 Mar; 11(1):36. PubMed ID: 29514683
[TBL] [Abstract][Full Text] [Related]
25. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation.
Green AS; Chapuis N; Maciel TT; Willems L; Lambert M; Arnoult C; Boyer O; Bardet V; Park S; Foretz M; Viollet B; Ifrah N; Dreyfus F; Hermine O; Moura IC; Lacombe C; Mayeux P; Bouscary D; Tamburini J
Blood; 2010 Nov; 116(20):4262-73. PubMed ID: 20668229
[TBL] [Abstract][Full Text] [Related]
26. [Exploration of novel therapeutic targets in acute myeloid leukemia via genome-wide CRISPR screening].
Yamauchi T
Rinsho Ketsueki; 2019; 60(7):810-817. PubMed ID: 31391371
[TBL] [Abstract][Full Text] [Related]
27. Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo.
Su Y; Li X; Ma J; Zhao J; Liu S; Wang G; Edwards H; Taub JW; Lin H; Ge Y
Biochem Pharmacol; 2018 Feb; 148():13-26. PubMed ID: 29208365
[TBL] [Abstract][Full Text] [Related]
28. Chronic IL-15 Stimulation and Impaired mTOR Signaling and Metabolism in Natural Killer Cells During Acute Myeloid Leukemia.
Bou-Tayeh B; Laletin V; Salem N; Just-Landi S; Fares J; Leblanc R; Balzano M; Kerdiles YM; Bidaut G; Hérault O; Olive D; Aurrand-Lions M; Walzer T; Nunès JA; Fauriat C
Front Immunol; 2021; 12():730970. PubMed ID: 34975835
[TBL] [Abstract][Full Text] [Related]
29. Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia.
Chen LS; Yang JY; Liang H; Cortes JE; Gandhi V
Leuk Lymphoma; 2016 Dec; 57(12):2863-2873. PubMed ID: 27054578
[TBL] [Abstract][Full Text] [Related]
30. Acquired expression of osteopontin selectively promotes enrichment of leukemia stem cells through AKT/mTOR/PTEN/β-catenin pathways in AML cells.
Mohammadi S; Ghaffari SH; Shaiegan M; Zarif MN; Nikbakht M; Akbari Birgani S; Alimoghadam K; Ghavamzadeh A
Life Sci; 2016 May; 152():190-8. PubMed ID: 27063991
[TBL] [Abstract][Full Text] [Related]
31. AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer.
Chan JC; Hannan KM; Riddell K; Ng PY; Peck A; Lee RS; Hung S; Astle MV; Bywater M; Wall M; Poortinga G; Jastrzebski K; Sheppard KE; Hemmings BA; Hall MN; Johnstone RW; McArthur GA; Hannan RD; Pearson RB
Sci Signal; 2011 Aug; 4(188):ra56. PubMed ID: 21878679
[TBL] [Abstract][Full Text] [Related]
32. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
[TBL] [Abstract][Full Text] [Related]
33. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
[TBL] [Abstract][Full Text] [Related]
34. Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid Leukemia.
Bhayadia R; Krowiorz K; Haetscher N; Jammal R; Emmrich S; Obulkasim A; Fiedler J; Schwarzer A; Rouhi A; Heuser M; Wingert S; Bothur S; Döhner K; Mätzig T; Ng M; Reinhardt D; Döhner H; Zwaan CM; van den Heuvel Eibrink M; Heckl D; Fornerod M; Thum T; Humphries RK; Rieger MA; Kuchenbauer F; Klusmann JH
J Clin Oncol; 2018 Apr; 36(10):1007-1016. PubMed ID: 29432078
[TBL] [Abstract][Full Text] [Related]
35. mTORC1 signaling controls multiple steps in ribosome biogenesis.
Iadevaia V; Liu R; Proud CG
Semin Cell Dev Biol; 2014 Dec; 36():113-20. PubMed ID: 25148809
[TBL] [Abstract][Full Text] [Related]
36. Reduction of ribosome biogenesis with activation of the mTOR pathway in denervated atrophic muscle.
Machida M; Takeda K; Yokono H; Ikemune S; Taniguchi Y; Kiyosawa H; Takemasa T
J Cell Physiol; 2012 Apr; 227(4):1569-76. PubMed ID: 21678406
[TBL] [Abstract][Full Text] [Related]
37. Activation of orphan receptor GPR132 induces cell differentiation in acute myeloid leukemia.
Yi C; He J; Huang D; Zhao Y; Zhang C; Ye X; Huang Y; Nussinov R; Zheng J; Liu M; Lu W
Cell Death Dis; 2022 Nov; 13(11):1004. PubMed ID: 36437247
[TBL] [Abstract][Full Text] [Related]
38. P19ARF and RasV¹² offer opposing regulation of DHX33 translation to dictate tumor cell fate.
Zhang Y; Saporita AJ; Weber JD
Mol Cell Biol; 2013 Apr; 33(8):1594-607. PubMed ID: 23401854
[TBL] [Abstract][Full Text] [Related]
39. Antileukemic activity of rapamycin in acute myeloid leukemia.
Récher C; Beyne-Rauzy O; Demur C; Chicanne G; Dos Santos C; Mas VM; Benzaquen D; Laurent G; Huguet F; Payrastre B
Blood; 2005 Mar; 105(6):2527-34. PubMed ID: 15550488
[TBL] [Abstract][Full Text] [Related]
40. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.
Harada M; Benito J; Yamamoto S; Kaur S; Arslan D; Ramirez S; Jacamo R; Platanias L; Matsushita H; Fujimura T; Kazuno S; Kojima K; Tabe Y; Konopleva M
Oncotarget; 2015 Nov; 6(35):37930-47. PubMed ID: 26473447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
